Literature DB >> 25841530

Adaptive clinical trial designs in oncology.

Yong Zang1, J Jack Lee2.   

Abstract

Adaptive designs have become popular in clinical trial and drug development. Unlike traditional trial designs, adaptive designs use accumulating data to modify the ongoing trial without undermining the integrity and validity of the trial. As a result, adaptive designs provide a flexible and effective way to conduct clinical trials. The designs have potential advantages of improving the study power, reducing sample size and total cost, treating more patients with more effective treatments, identifying efficacious drugs for specific subgroups of patients based on their biomarker profiles, and shortening the time for drug development. In this article, we review adaptive designs commonly used in clinical trials and investigate several aspects of the designs, including the dose-finding scheme, interim analysis, adaptive randomization, biomarker-guided randomization, and seamless designs. For illustration, we provide examples of real trials conducted with adaptive designs. We also discuss practical issues from the perspective of using adaptive designs in oncology trials.

Entities:  

Keywords:  Adaptive design; adaptive randomization; biomarker-guided design; interim analysis; seamless design

Year:  2014        PMID: 25841530     DOI: 10.3978/j.issn.2304-3865.2014.06.04

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


  8 in total

1.  Response adaptive randomization procedures in seamless phase II/III clinical trials.

Authors:  Hongjian Zhu; Jin Piao; J Jack Lee; Feifang Hu; Lixin Zhang
Journal:  J Biopharm Stat       Date:  2019-08-27       Impact factor: 1.051

2.  Clinical Trial Adaptation by Matching Evidence in Complementary Patient Sub-groups of Auxiliary Blinding Questionnaire Responses.

Authors:  Ognjen Arandjelović
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

3.  PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.

Authors:  M R Trusheim; A A Shrier; Z Antonijevic; R A Beckman; R K Campbell; C Chen; K T Flaherty; J Loewy; D Lacombe; S Madhavan; H P Selker; L J Esserman
Journal:  Clin Pharmacol Ther       Date:  2016-10-19       Impact factor: 6.875

4.  RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.

Authors:  Avinash Gupta; Corran Roberts; Finn Tysoe; Matthew Goff; Jenny Nobes; James Lester; Ernie Marshall; Carie Corner; Virginia Wolstenholme; Charles Kelly; Adelyn Wise; Linda Collins; Sharon Love; Martha Woodward; Amanda Salisbury; Mark R Middleton
Journal:  Br J Cancer       Date:  2016-10-06       Impact factor: 7.640

Review 5.  Innovative highlights of clinical drug trial design.

Authors:  Daohong Chen; Eric Yining Qi
Journal:  Transl Res       Date:  2020-06-03       Impact factor: 7.012

6.  Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.

Authors:  Revathi Ananthakrishnan; Stephanie Green; Mark Chang; Gheorghe Doros; Joseph Massaro; Michael LaValley
Journal:  Contemp Clin Trials Commun       Date:  2016-11-24

Review 7.  Arguing for Adaptive Clinical Trials in Sepsis.

Authors:  Victor B Talisa; Sachin Yende; Christopher W Seymour; Derek C Angus
Journal:  Front Immunol       Date:  2018-06-28       Impact factor: 7.561

Review 8.  Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance.

Authors:  Peter T Harrison; Paul H Huang
Journal:  Essays Biochem       Date:  2018-10-26       Impact factor: 8.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.